This Department of Health and Human Services (HHS)/HRSA grant aims to increase the uptake of Long-Acting Injectable Antiretrovirals (LAI ARV) among people with HIV, particularly in minority populations, to address health inequities and stigma. This grant is for enhancing viral suppression and client retention, crucial for achieving national HIV/AIDS goals. The program will fund a Coordination and Evaluation Provider (CEP) to develop, implement, and refine clinical protocols for LAI ARV administration. The CEP will then subaward up to ten demonstration sites, prioritizing those in Ending the HIV Epidemic (EHE) jurisdictions. This initiative seeks to establish effective strategies for LAI ARV access, improving treatment adherence and outcomes for patients, especially those facing challenges with oral therapies.
Opportunity ID: 339669
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HRSA-22-155 |
| Funding Opportunity Title: | Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=ca614928-5387-4da4-83ae-fa599b4bd10f |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 93.899 — Minority HIV/AIDS Fund (MHAF) |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 21, 2022 |
| Last Updated Date: | Apr 21, 2022 |
| Original Closing Date for Applications: | Jun 21, 2022 |
| Current Closing Date for Applications: | Jun 21, 2022 |
| Archive Date: | – |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $1,500,000 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Independent school districts County governments Private institutions of higher education Public and State controlled institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) |
| Additional Information on Eligibility: | Eligible applicants include entities eligible for funding under Parts A-D of Title XXVI of the Public Health Service (PHS) Act, including public and nonprofit private entities, state and local governments, academic institutions; local health departments; nonprofit hospitals and outpatient clinics; colleges and universities; community health centers receiving support under Section 330 of the PHS Act; faith-based and community-based organizations; and Indian Tribes or Tribal organizations with or without federal recognition. Proof of applicant status (e.g., proof of non-profit status) may be requested or required. |
Additional Information
| Agency Name: | Health Resources and Services Administration |
| Description: | This notice announces the opportunity to apply for funding under the Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV cooperative agreement Increasing viral suppression and client retention in care are critical components of meeting the goals of the National HIV/AIDS Strategy (2022-2025) and ending the HIV epidemic. In order to reach these goals, it is imperative for HIV care communities to address health care inequities. With the advent of FDA-approved long-acting injectable (LAI) antiretroviral (ARV) medication formulations, initiatives that promote, facilitate, and evaluate the uptake and ongoing utilization of LAI ARV medication may improve clinical outcomes for people with HIV, especially for minority populations who continue to face disparate health care inequities and stigma. This project is designed to develop protocols, implement them and modify as needed, to increase uptake of LAI ARV medications among people of color with HIV, since LAI ARV medications may offer benefits in addressing health inequities and achieving viral suppression. In addition to alleviating challenges associated with oral medications, ongoing utilization of LAI ARV medications in lieu of oral regimens may potentially reduce HIV-related stigma and enhance protection of health privacy. While there are some unique clinical and social benefits to this injectable drug formulation, some aspects of its distribution, administration requirements, and billing have already hindered uptake and utilization within the Ryan White HIV/AIDS Program (RWHAP). As minority populations have historically experienced significant disparities in accessing care and treatment, including the health literacy and access to health care coverage options necessary to engage in care, developing interventions to increase the uptake of LAI ARV medication formulations will help to proactively address and potentially reduce or prevent disparities minority communities may face in accessing this breakthrough therapy. The main objective of this program is to develop and implement protocols for successful use of LAI ARV medication within clinical practice. This program will fund 1 organization to serve as the Coordination and Evaluation Provider (CEP). The CEP must have the capacity and infrastructure (e.g., staffing/personnel, trainings, clinical systems, data collection and reporting, protocol and implementation evaluation) to support development, implementation, and refinement of LAI ARV medication administration protocols with the goal of replicating and expanding successful protocols. The recipient will solicit and subaward up to 10 demonstration sites (subrecipients) to implement these co-developed protocols and collect data from direct patient care, with priority given to entities located within EHE jurisdictions. HRSA anticipates that through evaluation and scale-up of LAI ARV medication administration protocols, patients with historic difficulty accessing or continuing oral HIV therapy can be bridged to this treatment modality, thus improving viral suppression and retention in care, especially among racial and ethnic minorities. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Department of Health and Human Services, Health Resources and Services Administration
srobilotto@hrsa.gov Email:srobilotto@hrsa.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 339669 Full Announcement-HRSA-22-155 -> HAB HRSA-22-155 (U1S) MHAF LAI_Final.pdf
Packages
| Agency Contact Information: | Department of Health and Human Services, Health Resources and Services Administration srobilotto@hrsa.gov Email: srobilotto@hrsa.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.899 | HRSA-22-155 | Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV | PKG00273570 | Apr 21, 2022 | Jun 21, 2022 | View |
Package 1
Mandatory forms
339669 SF424_4_0-4.0.pdf
339669 AttachmentForm_1_2-1.2.pdf
339669 PerformanceSite_4_0-4.0.pdf
339669 ProjectNarrativeAttachments_1_2-1.2.pdf
339669 GG_LobbyingForm-1.1.pdf
339669 BudgetNarrativeAttachments_1_2-1.2.pdf
339669 SF424A-1.0.pdf
339669 Key_Contacts_2_0-2.0.pdf
339669 Project_AbstractSummary_2_0-2.0.pdf
Optional forms
339669 SFLLL_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
